LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Отворен

17.47 0.69

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

18.21

Ключови измерители
By Trading Economics
Приходи	-6.4M -20M
Продажби	-807K 71M
EPS	-0.13
Марж на печалбата	-28.24
Служители	624
EBITDA	-7.9M -14M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+16.19% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	121M 2.4B
Предишно отваряне	16.78
Предишно затваряне	17.47

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.06.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9.06.2026 г., 23:45 ч. UTC

Придобивния, сливания и поглъщания

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9.06.2026 г., 23:44 ч. UTC

Придобивния, сливания и поглъщания

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9.06.2026 г., 23:44 ч. UTC

Придобивния, сливания и поглъщания

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9.06.2026 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9.06.2026 г., 23:35 ч. UTC

Пазарно говорене

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9.06.2026 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9.06.2026 г., 22:05 ч. UTC

Придобивния, сливания и поглъщания

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9.06.2026 г., 22:05 ч. UTC

Придобивния, сливания и поглъщания

Samsung: Additional Investment Makes It Largest Shareholder in Element

9.06.2026 г., 22:05 ч. UTC

Придобивния, сливания и поглъщания

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9.06.2026 г., 20:51 ч. UTC

Печалби

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.06.2026 г., 20:09 ч. UTC

Пазарно говорене

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9.06.2026 г., 19:36 ч. UTC

Пазарно говорене

Cattle Climbs as Crude Oil Falls -- Market Talk

9.06.2026 г., 19:32 ч. UTC

Пазарно говорене

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9.06.2026 г., 19:25 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9.06.2026 г., 19:00 ч. UTC

Пазарно говорене

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9.06.2026 г., 18:52 ч. UTC

Придобивния, сливания и поглъщания

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9.06.2026 г., 18:47 ч. UTC

Пазарно говорене

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9.06.2026 г., 18:37 ч. UTC

Пазарно говорене

Canada's Cooling Trade With the U.S. -- Market Talk

9.06.2026 г., 18:27 ч. UTC

Пазарно говорене

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9.06.2026 г., 17:35 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9.06.2026 г., 17:30 ч. UTC

Пазарно говорене

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9.06.2026 г., 16:34 ч. UTC

Пазарно говорене

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

9.06.2026 г., 15:28 ч. UTC

Пазарно говорене

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9.06.2026 г., 15:25 ч. UTC

Пазарно говорене

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

16.19% нагоре

12-месечна прогноза

Среден 20.17 USD 16.19%

Висок 22 USD

Нисък 18 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.